Biocryst Pharmaceuticals (BCRX) Current Assets (2010 - 2026)

Biocryst Pharmaceuticals has reported Current Assets for 17 years, with the latest figure at $373.6 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 8.87% year-over-year to $373.6 million; the trailing twelve-month figure through Mar 2026 stood at $373.6 million (down 8.87% YoY), and the FY2025 full-year result was $404.3 million, down 4.18% from the prior year.
• Current Assets for Q1 2026 stood at $373.6 million, down from $404.3 million in the prior quarter.
• The five-year high for Current Assets was $516.5 million in Q4 2022, with the low at $355.7 million in Q3 2025.
• Historically, Current Assets has averaged $449.1 million across 5 years, with a median of $447.1 million in 2024.
• Annual changes were most pronounced in 2022 — Current Assets soared 101.39% — and 2024, when it slipped 28.88%.
• Biocryst Pharmaceuticals' Current Assets stood at $516.5 million in 2022, then slipped by 3.98% to $496.0 million in 2023, then slipped by 14.92% to $422.0 million in 2024, then fell by 4.18% to $404.3 million in 2025, then slipped by 7.6% to $373.6 million in 2026.
• The last three Current Assets figures came in at $373.6 million (Q1 2026), $404.3 million (Q4 2025), and $355.7 million (Q3 2025), per Business Quant data.